MEDIUM confidence: 100% data completeness, but the composite (51) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Not enough return history to estimate factor exposures — 28 of 36 months required. This stock is too recently listed (or has too short a price history) for a reliable Fama-French regression.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $119 avg across 9 analysts.
Buy-rated share 100% → 100% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $0.04 | $0.20 | +411.8% |
| Jun 2026 | $-0.03 | $0.16 | +637.5% |
| Mar 2026 | $-0.11 | $0.04 | +136.7% |
| Dec 2025 | $-0.17 | $0.10 | +158.9% |
| Sep 2025 | $-0.34 | $-0.03 | +91.1% |
| Jun 2025 | $-0.32 | $-0.15 | +53.3% |
| Mar 2025 | $-0.39 | $-0.18 | +53.7% |
| Dec 2024 | $-0.40 | $-0.21 | +47.5% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$13.7M over 180 days (0 open-market buys, 61 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $506M— | $600M+18.5% | $628M+4.7% | $887M+41.2% | $1.3B+48.5% |
| EPS (dil.) | $-1.45— | $-1.58n/m | $-2.01n/m | $-7.48n/m | $-1.78n/m |
| Free Cash Flow | -$103M— | -$15Mn/m | -$17Mn/m | $31Mn/m | $253M+708.1% |
| Gross Margin | 53.3% | 53.4%+0.1pp | 62.1%+8.7pp | 70.0%+8.0pp | 80.1%+10.1pp |
| Operating Margin | -49.4% | -43.6%+5.7pp | -48.8%-5.2pp | -127.9%-79.1pp | -26.2%+101.7pp |
| Net Margin | -50.3% | -46.3%+4.0pp | -56.4%-10.1pp | -130.3%-73.9pp | -26.5%+103.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 18.5%/yr (revenue basis).
Base free cash flow $89M (avg FY2024–FY2026; latest year $253M) · equity value $25.6B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 51 for RBRK suggests a neutral outlook, with the stock's strong growth and momentum offset by its poor value and mixed profitability. The growth category scores high on revenue and EPS growth, with notable increases of 48.5% and 76.2%, respectively, while momentum is also strong with a 72.6% return over the past year. However, the stock trades at a premium, with a P/E of -97.7 and EV/EBITDA of -136.7, contributing to its low value score. The long-term and short-term scores diverge, with the short-term score 14 points higher, indicating a recent surge in performance.